Alessandra Gennari MD PhD
@ALEDIGNUS12
Followers
936
Following
796
Media
18
Statuses
503
Professor of Oncology @UniAvogadro & Medical Oncologist Head Division of Oncology Maggiore della Carità Hospital Novara IT #BreastCancer #MolecularImaging #IO
Genova, Liguria
Joined June 2019
Insieme alla cura dei pazienti e alla ricerca, la formazione dei giovani oncologi è una delle componenti più belle del nostro lavoro. Quando il risultato sono eccellenze come Matteo Lambertini, si viene ripagati di tutto l’impegno e le energie investiti!
Ultima foto da #ESMO25 per ringraziare la persona speciale che mi ha fatto crescere in ambito professionale, che mi accompagna ancora oggi e che sicuramente continuerà a sostenermi in futuro…insomma, sempre #INSIEME a @delmastro_lucia 💪🙌😍🤩 @AIOMtweet @OncoAlert @UniGenova
1
8
23
Absolutely AMAZING discussion by Ana Garrido-Castro on ASCENT-03 and TROPiON-Breast02!!! @DFCI_BreastOnc #ESMO25 @OncoAlert
3
24
112
What’s interesting is the control arm in post-Monarch (CDK46 inhibitor prior treatment) was fulvestrant alone w/ ~50% mutPIK3CA and had mPFS 5.3 months. Sometimes it does help us compare how different populations of post-CDK4/6 inhibitor patients can be. #ESMO25
Excellent question from the audience. Why in the world are we still using single agent fulvestrant control arms in 2025? Apparently @US_FDA mandated this in Viktoria 1.
1
7
20
#ESMO25: Positive phase III #ClinicalTrial data with T-DXd in high-risk, HER2+ #EarlyBreastCancer suggest that a paradigm change in the treatment of these patients may be imminent. Read more in the #ESMODailyReporter 📌 https://t.co/Iiva5Y6Qbn
#BreastCancer #ADC
@E_de_Azambuja
0
5
19
Interesting news re: abemaciclib in MonarchE trial. At 5 years, the OS data in @JCO_ASCO was NS with HR 0.9.
Very big news out today-- adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 yrs of f/u! Showing OS benefit in this setting is not easy & nice to see what an incredible impact adj cdk4/6i can have for our patients! https://t.co/pxI4RxPxXz
10
12
58
La preservazione della fertilità è parte essenziale della cura in oncologia. Grazie all’@ass_coscioni per aver dato spazio a questo tema, che riguarda il futuro di donne e uomini colpiti da tumore. Parlare, informare, accompagnare: è anche questo prendersi cura.
1
1
5
Onorata di intervenire a #ESCCardioOnco2025 La collaborazione tra diversi specialisti è un esempio concreto di quanto la multidisciplinarietà sia cruciale nella cura del cancro @escardio @AIOMtweet
#cardiooncology #collaborazione #oncologia #cardiologia #INSIEME
0
9
32
Da oggi al 14 con @AIOMtweet @AiomFondazione @AIRC_it @_sirm saremo al Porto Antico del @ComunediGenova per parlare di #prevenzione in oncologia in occasione dell'arrivo del @tourvespucci
@delmastro_lucia @matteolambe @CarloGenova5 @Poggio_Fra @DSoldatoMD @boutrosand @UniGenova
Manca pochissimo all'ultima tappa del #tourvespucci: vi aspettiamo il 10 giugno a Genova. #wearevespucci #prevenzione #fondazioneaiom
@tourvespucci
@AIRC_it
@_sirm
1
12
12
RT @PTarantinoMD: SERENA6 presentation by Nick Turner. What it shows: that a switch to camizestrant/CDKi vs continuing AI/CDKi can keep pts…
0
1
0
NEWS FROM INDUSTRY Source AstraZeneca https://t.co/BCclFiUTeS The Phase III DESTINY-Breast09 trial marks a significant advancement in HER2-positive metastatic #BreastCancer treatment, showing that trastuzumab deruxtecan combined with pertuzumab delivers a statistically
1
37
71
📣ESMO Living Guidelines on Metastatic Breast Cancer: 👉Just updated with the latest recommendations and algorithms in an interactive format. 🔗 https://t.co/kjGexgJ1WZ
#ClinicalPracticeGuideline
4
25
60
T-DXd approval finally expanded also in Europe to patients with HR+/HER2-0 (ultralow) disease or chemo-naive pts. Appealing post-ET option for patients with aggressive disease course. Congrats @curijoey for leading the DB06 trial that backed this approval! https://t.co/Sya2Lo9G7H
2
21
110
Important analyses. Thinking about treatment selection by actual prognosis/risk, and not by study eligibility, is a long standing approach in breast cancer. As was discussed @SG_BCC St Gallen last month, it should be applied to decision making in adjuvant CDK46i selection, too.
I want to thank all those have contributed, including all the investigators of MIG/GIM trials, all the patients included, and all co-authors, particularly @BlondeauxEva, @matteolambe and @delmastro_lucia for giving me the chance to conduct this analysis! 🤝 @OncoAlert
0
15
47
Our Collaborators at @high5md are here in San Antonio bringing you LIVE Reports from #SABCS24 🇺🇸from TOP international Experts🌐in #BreastCancer Find their Coverage here: https://t.co/ih1IbQABah Experts include @hoperugo @curijoey @Prof_Nadia_H @ALEDIGNUS12 @stolaney1 and many
0
5
10
Just released the 2nd version of the @myESMO Essentials for Clinicians - Breast Cancer. Honoured to have contributed w a chapter purely focused on BC in #young women. Thanks to @matteolambe for this opportunity and to @myESMO editorial team for this effort! @OncoAlert
2
14
45
Oggi 13 maggio ⌚️ alle ore 14.00 I Laboratori dell’Oncologia di Domani: Molecular Tumor Board Un Live Webinar con Responsabili Scientifici Proff. Alessandra Gennari e Valentina Guarneri. Programma ed iscrizioni: https://t.co/Uz6DMG4ly3
#MTB @ALEDIGNUS12
0
2
1
Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer | Journal of Clinical Oncology https://t.co/zlRFEFRbhb New CANTO data out! @DSoldatoMD Lee Jones, @GroupeUnicancer @FAndreMD @dimeglio_anto @marti_pagliuca @AliceFranzoi @GR_SurvOnc
ascopubs.org
PURPOSEPostdiagnosis exercise is associated with lower breast cancer (BC) mortality but its link with risk of recurrence is less clear. We investigated the impact and dose-response relationship of...
3
34
85
🚀Don’t miss out on this must-read review on the role of genomic tests in guiding adjuvant ET for #breastcancer. 🌟Stay ahead with the latest insights on this hot topic!
❓ How can gene expression assays guide the choice of adjuvant endocrine therapy in #breastcancer? 👉🏻 Check out our review in @CCR_AACR
@GaiaGriguolo @vitti10 @FedeMiglietta
https://t.co/7toOfkVqwR
0
1
8
Couldn’t agree more. Fantastic work by #myriamChalabi and colleagues #Oncoalert
Super proud of my colleague and rockstar @MyriamChalabi with @HaanenJohn @NKI_nl. With short-term IO most of the MMRd colon cancer responded beautifully! #makingimpact
0
2
4